Tempest Therapeutics, Inc. financial data

Symbol
TPST on Nasdaq
Industry
Pharmaceutical Preparations
Location
2000 Sierra Point Parkway, Suite 400, Brisbane, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Millendo Therapeutics, Inc. (to 7/1/2021), OvaScience, Inc. (to 12/6/2018)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 265 % -7.52%
Debt-to-equity 127 % -60.3%
Return On Equity -187 % +50.4%
Return On Assets -82.6 % +8.28%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 43.6M shares +127%
Common Stock, Shares, Outstanding 26.6M shares +85.5%
Entity Public Float 16M USD -27.9%
Common Stock, Value, Issued 27K USD +92.9%
Weighted Average Number of Shares Outstanding, Basic 25.8M shares +82.7%
Weighted Average Number of Shares Outstanding, Diluted 25.8M shares +82.7%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 13.7M USD +19.5%
Operating Income (Loss) -35.6M USD -16.5%
Nonoperating Income (Expense) 103K USD +97.4%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -35.5M USD -14.2%
Earnings Per Share, Basic -1.53 USD/shares +24.6%
Earnings Per Share, Diluted -1.53 USD/shares +24.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 22.1M USD +98.9%
Other Assets, Current 385K USD +65.9%
Assets, Current 23.6M USD +91.6%
Property, Plant and Equipment, Net 932K USD +1.19%
Operating Lease, Right-of-Use Asset 8.9M USD -14.2%
Other Assets, Noncurrent 448K USD +14%
Assets 33.8M USD +41.1%
Accounts Payable, Current 1.7M USD +49%
Employee-related Liabilities, Current 1.4M USD +50.6%
Accrued Liabilities, Current 1.46M USD -26.9%
Liabilities, Current 14M USD +88.3%
Operating Lease, Liability, Noncurrent 8.41M USD -10.4%
Liabilities 22.4M USD -11.1%
Retained Earnings (Accumulated Deficit) -193M USD -22.5%
Stockholders' Equity Attributable to Parent 11.5M USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 11.5M USD
Liabilities and Equity 33.8M USD +41.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.19M USD +13.5%
Net Cash Provided by (Used in) Financing Activities 450K USD +923%
Net Cash Provided by (Used in) Investing Activities -168K USD -265%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 26.6M shares +85.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -8.31M USD -45.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 22.9M USD +99.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 326K USD +11.6%
Deferred Tax Assets, Valuation Allowance 165M USD +5.87%
Deferred Tax Assets, Gross 168M USD +5.42%
Operating Lease, Liability 11.7M USD +239%
Depreciation 426K USD -17%
Payments to Acquire Property, Plant, and Equipment 168K USD +265%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -8.95M USD -9.12%
Lessee, Operating Lease, Liability, to be Paid 16.9M USD +358%
Property, Plant and Equipment, Gross 2.3M USD -10.7%
Operating Lease, Liability, Current 828K USD -25.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.1M USD +27.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.61M USD +63%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 5.16M USD +2194%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.86M USD +320%
Deferred Tax Assets, Operating Loss Carryforwards 137M USD +4.23%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 4.92M USD +5.87%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.93M USD
Additional Paid in Capital 205M USD +30.8%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 2.97M USD -14.6%
Share-based Payment Arrangement, Expense 5.07M USD +170%
Interest Expense 1.49M USD -1.97%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%